By W. Schramm, H. Krebs (auth.), Professor Dr. med. Inge Scharrer, Professor Dr. med. Wolfgang Schramm (eds.)

ISBN-10: 3540009027

ISBN-13: 9783540009023

ISBN-10: 3642182607

ISBN-13: 9783642182600

Show description

Read or Download 33rd Hemophilia Symposium: Hamburg 2002 PDF

Similar nonfiction_10 books

Download e-book for iPad: Topics in Micrometeorology. A Festschrift for Arch Dyer by B. B. Hicks (auth.), Bruce B. Hicks (eds.)

Within the micrometeorological literature, reference is usually made to the 'Businger-Dyer Profiles' or the 'Dyer-Businger profiles/relations' with no concerning the beginning of those kin. for instance, within the textbook on 'Atmospheric Turbulence' by way of Panofsky and Dutton (1984) on p. 134, reference is made to the 'Businger-Dyer formula'.

Download e-book for kindle: Toward the Integration of Theory, Methods, Research, and by Gary T. Moore (auth.), Gary T. Moore, Robert W. Marans

This fourth quantity within the Advances in setting, habit, and layout sequence maintains the cause of previous volumes via exploring new instructions within the multidisciplinary environment-behavior (EB or EBS) box. The sequence is prepared round a framework of concept, tools, learn, and usage that a few say has outlined the sector for the earlier 15 years.

Extra info for 33rd Hemophilia Symposium: Hamburg 2002

Example text

7e). Arranging data for greater periods, one can see this effect obviously. Clustering data for the years 1982 to 1993 and 1993 to 2002 gives us a statistical significant difference between these periods (p < 0,001), implicating a gradually rise in cancer deaths (see Fig. 7f). The impact of liver disease on death causes remains uncertain any longer. However clustered data for the years 1982 to 1993 and 1993 to 2002 show a difference close to statistical significance (p < 0,059, see Fig. 7d), suggesting a future increase.

W. Schoenlein Prize was awarded on November 08, 2002 for the 15th time to: Prof. Thierry VandenDriessche. He was born in 1965 in Ostende (Belgium). He is working in the Center of Transgene Technology and Gene Therapy of the University of Leuven and he is a visiting professor at the Free University in Brussels. He published 61 publications in well known peer-reviewed journals during the period of 1989–2002. His research projects include methods of gene transfer and the gene therapy of hemophilia.

3). We still have 3⁄4 patients substituting on demand, type A 319, type B 77. Ninety (17%) patients use prophylactic treatment, mostly children. In 46 (9%) there are still no data available. Moreover we can register different factor substitutes (Fig. 4). Nearly half of the patients with hemophilia A have adopted treatment with recombinant factor VIII (212/49%), which has considerably increased in comparison to last year (180/42%). Consequently plasma-derived factor VIII sub- 450 on demand 400 396 prophylaxis no data 350 319 300 250 200 150 100 50 90 77 77 46 38 13 8 0 Hemophilia A: 434 Hemophilia B: 98 Total: 532 Fig.

Download PDF sample

33rd Hemophilia Symposium: Hamburg 2002 by W. Schramm, H. Krebs (auth.), Professor Dr. med. Inge Scharrer, Professor Dr. med. Wolfgang Schramm (eds.)

by James

Rated 4.19 of 5 – based on 42 votes